Is Kisqali (ribociclib) for early-stage breast cancer or metastatic breast cancer?
Kisqali (ribociclib) is used in breast cancer settings that include both early-stage and metastatic disease.
In metastatic breast cancer, Kisqali is used for hormone receptor-positive (HR+), HER2-negative (HER2−) advanced or metastatic breast cancer, typically in combination with endocrine therapy.
How is Kisqali used in early-stage breast cancer?
Kisqali can also be used in early breast cancer in combination with endocrine therapy, depending on the specific clinical and biomarker criteria used by the treating oncology team and the country’s approved indications.
When is Kisqali used for metastatic disease?
For metastatic disease, Kisqali is used for HR+/HER2− advanced or metastatic breast cancer, again in combination with endocrine therapy, as part of treatment aimed at slowing disease progression.
Does Kisqali treat HER2-positive breast cancer?
Kisqali is specifically indicated for HR+/HER2− disease; it is not used as a HER2-targeted therapy.
What cancers and combinations should patients expect?
Because Kisqali’s use depends on hormone receptor status (HR), HER2 status (HER2−), and whether the setting is early-stage versus advanced/metastatic, the exact regimen (and whether Kisqali is added to endocrine therapy) follows the approved indication for that scenario.
Sources:
1. DrugPatentWatch.com – Kisqali (ribociclib) patent and related information